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The papillomavirus (PV) E2 protein plays a role in recruiting viral and cellular DNA replication factors, such as PV E1 or RPA to PV
genomes. Using both purified proteins and through co-precipitation, it was determined that HPV-11 E2 binds human topoisomerase I. E2 can
stimulate topoisomerase I DNA relaxation activity 3- to 4-fold. Conversely, topoisomerase I is unable to stimulate E2 DNA binding. These
findings suggest that stimulation of topoisomerase I by E2 may help promote efficient relaxation of the torsional stress induced by PV DNA
replication.
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Papillomaviruses (PVs) are small, nonenveloped, circular
DNA viruses (Cheah and Looi, 1998; Chen et al., 1982). PV
E2 is a multi-purpose regulator of viral transcription that is
needed to recruit the hexameric E1 helicase to origin
sequences (Sarafi and McBride, 1995; Sedman et al., 1997).
Along with E1 and E2, PV DNA replication is carried out
entirely by cellular factors (Kuo et al., 1994; MacPherson et
al., 1994; Melendy et al., 1995; Yang and Botchan, 1990; Yang
et al., 1993). One of the important cellular factors required for
PV DNA replication is human topoisomerase I (topo I) (Yang
et al., 1993). Topo I is an ATP-independent protein that
modifies the topology of supercoiled DNA, acting as a swivel
to decrease torsional stress on DNA (Champoux, 2001;
Stewart and Champoux, 2001).
E2 has been demonstrated to interact with or modulate the
activities of various cellular proteins such as: SP1, RPA, DNA
polymerase α-primase, and p53 (Li et al., 1991; Loo and⁎ Corresponding author. University at Buffalo, Department of Microbiology
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Previously, we reported that the PV E1 helicase can bind to and
stimulate topo I (Clower et al., 2006). These findings led us to
evaluate whether the other PV replication protein, E2, is
involved in topo I modulation. Therefore, E2 was tested for the
ability to bind to and stimulate topo I. The roles of E1, E2, and
topo I in PV DNA replication are discussed.
The HPV-11 E2 protein and human topo I interact
To ascertain whether the PV E2 protein interacts with
human topo I, ELISA-based protein interaction assays were
performed as described (Loo and Melendy, 2004). Briefly,
wells were coated for 60 min at room temperature (RT) with
purified topo I or GST-E2 (3.0 pmol) as the immobilized
protein. Increasing concentrations of the second protein were
added to the wells in the presence of excess micrococcal
nuclease (to digest any residual DNA). The wells were
washed, and a polyclonal anti-GST antibody (or an anti-topo I
antibody) was added to assess binding. In Fig. 1a, purified
topo I was immobilized in ELISA plate wells, GST-E2 (HPV-
11) was added and shown to bind to topo I. GST-YY1, GST
and BSA did not show appreciable interaction with topo I
(Fig. 1a and data not shown, respectively). Similar results
Fig. 1. E2 binds topoisomerase I. (a) ELISAs were performed using 3 pmol of topoisomerase I (topo I) as the immobilized protein. Increasing concentrations of the
indicated proteins (GST-E2, squares; GST, circles; GST-YY1, triangles) were added to the wells. Binding was detected using a polyclonal anti-GST antibody followed
by a secondary Hrp antibody. After developing, the absorbance was measured at 450 nm. The results represent three separate experiments; the range is demonstrated by
error bars. (b) ELISAs were performed using 3 pmol of GST-E2, open circles; BSA, closed triangles; or GST, open squares as the immobilized protein. Increasing
concentrations of topo I were added to the wells. Binding was detected using a monoclonal anti-topo I antibody followed by a secondary Hrp antibody. After
developing, the absorbance was measured at 450 nm. The results represent three separate experiments; the range is demonstrated by error bars. (c) GST-E2 co-
precipitation experiments were performed in which 10 or 50 μg of GST-E2 or GST were incubated with glutathione Sepharose beads in the presence of 5 mg of 293
(S100) cell extract or 50 μg of purified topo I. The beads were washed with high salt TBS (750 mM NaCl) three times and subjected to 12.5% SDS-PAGE.
Immunoblotting was performed using an anti-topo I mAb.
14 Rapid Communicationwere observed when the assay was carried out in reverse with
GST-E2 as the immobilized protein (using a monoclonal anti-
topo I antibody to detect topo I binding, Fig. 1b). Topo I
bound to E2 but did not show appreciable binding to GST or
BSA (Fig. 1b).
GST co-precipitations were also performed to confirm
binding between E2 and topo I. Glutathione beads were
incubated with either GST-E2 or GST and then 293 cell extract
(or purified topo I). Following incubation, the beads were
washed extensively in buffer containing 750 mM NaCl and
subjected to SDS-PAGE and immunoblots. Topo I was
detectable when 10 μg of GST-E2 was incubated with cell
extracts and produced a strong signal with 50 μg of GST-E2
(Fig. 1c). Conversely, 50 μg of GST did not co-precipitate
detectable topo I. These results demonstrate that E2 binds to
topo I not only as purified proteins but also within the context of
crude cell extracts.
E2 stimulates topo I activity
To determine whether the E2-topo I interaction modulates
topo I relaxation activity, topo I relaxation assays wereperformed as described (Stewart and Champoux, 2001), with
slight modifications. Briefly, plasmid template pUC119 was
incubated with 5 pg/μl of topo I for 30 min in the presence and
absence of GST-E2, GST or additional BSA (Fig. 2a and data
not shown, note that in Fig. 2a [lanes 1 and 2], it is difficult to
detect the intermediate DNA topoisomers due to the very low
level of topo I and the light exposure of the gel). Nonetheless,
increasing amounts of GST-E2 led to a clear increase in topo I
activity (Figs. 2a and b, 4-fold at 30 ng/μl). Greater than 30 ng/
μl of GST-E2 did not further increase topo I relaxation activity.
GST, a GST fusion with the transcription factor YY1, or
additional BSA did not stimulate the relaxation activity of topo I
(Fig. 2b). E2 (without a GST moiety) also stimulated topo I
DNA relaxation; and GST-E2 in the absence of topo I had no
intrinsic relaxation activity (data not shown). BPV-1 E2 showed
a similar degree of stimulation of human topo I (data not
shown).
Characterization of E2 stimulation of topo I
A plasmid template containing the HPV-11 origin of
replication (p7974-99; nucleotides 7974-99 of the HPV-11
Fig. 2. E2 stimulates topo I relaxation activity. (a) Topo I plasmid relaxation
assays were performed in the presence of increasing levels of GST-E2. Plasmid
template pUC119 (30 ng/μl) was incubated with 5 pg/μl of topo I (+) for 30 min
at 37 °C (lane 1). GST-E2 was added to the reaction at 7.5, 15, and 30 ng/μl in
lanes 4–6, respectively. Lane 3 shows pUC119 substrate alone. GST (30 ng/μl)
had no effect on topo I activity (lane 2). BSA was added to each reaction at
0.1 mg/ml. GST-E2 alone had no effect on pUC119 (data not shown). Arrows
show positions of relaxed (form II/IV) and supercoiled (form I) plasmid DNA.
(b) The degree of topo I stimulation was measured by the disappearance of the
supercoiled band. Topo I stimulation (of DNA relaxation), produced by E2 and
other proteins was calculated as described (see Materials and methods). The
results represent three or more separate experiments; the range is demonstrated
by error bars.
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determine if the PV origin of replication influences the
stimulation of topo I by E2 (compared to a nonorigin
plasmid; pUC119). Since the enzymatic activity of topo I
relaxes each plasmid template with different efficiency
depending on the precise topology and nucleotide sequence
(Cozzarelli, 1980), relaxation assays were performed and
quantitated via a topo I standard curve for each template
(Fig. 3a, see Materials and methods). Whether using DNA
templates without or with a PV origin, the degree of
stimulation was comparable, indicating that the stimulation
of topo I by E2 is origin independent (Fig. 3a).
To ascertain whether temporal addition of E2 or topo I to
a relaxation assay is important, order of addition experi-
ments were performed. Initially, a plasmid template was
incubated in relaxation buffer in the presence of topo I for 5
min on ice, followed by addition of E2. In this case, when
E2 was added as the second protein (at an optimal
concentration, 30 ng/μl), a significant stimulation of topo I
DNA relaxation was observed (approximately 4-fold, Fig. 3b
lanes 5 and 6). When the reverse order was tested (E2 as
the first protein), stimulation of topo I was still observed,
but the effect was less (approximately 2.5-fold, Fig. 3b,
lanes 3 and 4). Assays performed at lower concentrations of
E2 demonstrated similar effects (data not shown). In Fig.
3b, lanes 4 and 6 show that the addition of 4 mM ATP to
the E2 stimulated topo I relaxation assay had no effect.Topo I does not stimulate DNA binding of E2
To determine whether topo I can stimulate PV origin DNA
binding by E2, EMSAs were performed as described
(Sedman et al., 1997), in the presence of increasing amounts
of topo I. BPV-1 E2 was incubated with a radiolabeled DNA
fragment containing the BPV-1 minimal origin of replication
(60 nucleotides, 7914-27-BS9 of the BPV-1 genome contain-
ing a high affinity E2 binding site, Sedman and Stenlund,
1995) to determine a basal level of binding (Fig. 4a). Topo I
was then added to the EMSA reaction at increasing
concentrations. Over a broad range of topo I added (5 to
200 fmol), no effect on E2 binding was observed (Fig. 4a,
see b for quantitation). Lower levels of E2 were also used,
and similar results were observed (data not shown). Also, it
appears that E2 has no stimulatory effect on the DNA
binding activity of topo I at the concentrations tested in this
assay (Fig. 4a and data not shown). So while E2 binds and
stimulates topo I, topo I appears to have no appreciable effect
on E2 DNA binding.
Discussion
In this study, ELISA and co-immunoprecipitation experi-
ments demonstrate that human topo I interacts with the PV E2
protein. Using topo I relaxation assays, we determined that E2
stimulates topo I DNA relaxation activity. However, topo I had
no effect on the DNA binding of E2. We have shown that topo I
stimulates the binding of E1 to PVorigin sequences (Hu et al., in
press). These results may suggest possible complementary roles
for E2 and topo I at the PV origin. Potentially, E2 may bind to
the PV origin concurrently with E1 and topo I, of which the
latter may stimulate recruitment of the former in conjunction
with E2. For PV DNA replication to then ensue, efficient topo I
DNA relaxation is essential. Based on these findings, E2 may
participate in this process. Therefore, it is reasonable to suggest
that the E2-topo I interaction may play an important role in PV
DNA replication.
Materials and methods
Purification of plasmid DNA and recombinant proteins
To obtain negatively supercoiled template DNA, pUC119,
p7974-99 (a plasmid containing the HPV-11 origin of DNA
replication; nucleotides 7974-99) were purified from E. coli
(Qiagen® midi-prep) and further isolated using sucrose
gradient (5–20%, wt/vol) sedimentation. GST-E2 and GST
were purified from BL21-DE3-RIL codon plus E. coli using
the bacterial expression vectors described (Sun et al., 1998).
Briefly, all cultures were induced with IPTG at an O.D.600 nm
of 0.6 and grown overnight at 22 °C. The cells were
harvested and lysed by sonication. The lysate was bound to
GST-Sepharose beads. The beads were washed, and the
protein was eluted with 10 mM glutathione. The purified GST
proteins were dialyzed against buffer A (25 mM Tris–HCl
[pH 8.0], 10% glycerol [vol/vol], 1 mM Na2EDTA, 50 mM
Fig. 3. Characterization of E2 stimulation of topo I. (a) The PV origin of replication does not influence the stimulation of topo I by E2. Relaxation assays were
performed as described above using a PVorigin (p7974-99, a plasmid containing the HPV-11 origin of replication), or a nonorigin template (pUC119). Using a PV
origin template, the degree of topo I stimulation was measured by the disappearance of the supercoiled band, as described (see Materials and methods) and compared to
pUC119. The results represent three or more separate experiments; the range is demonstrated by error bars. (b) The order of addition is significant for topo I stimulation
by E2. Topo I plasmid relaxation assays were performed in the presence of GST-E2 (30 ng/μl). Plasmid template pUC119 (30 ng/μl) was incubated with 5 pg/μl of topo
I (+) for 30 min at 37 °C (lane 2). pUC119 alone is shown in lane 1. Topo I was pre-incubated with pUC119 in relaxation buffer for 5 min on ice; GST-E2 (30 ng/μl)
was then added to the pre-incubation for 30 min at 37 °C (lanes 5, 6 respectively, lane 6 also shows a reaction with 4 mMATP). In lanes 3 and 4, GST-E2 (30 ng/μl) was
pre-incubated with pUC119 in relaxation buffer for 5 min on ice; topo I (5 pg/μl) was added as the second protein (lane 4 also shows a reaction with 4 mM ATP). For
the first protein, below the photo, topo I is labeled T, ATP 4 mM is labeled A, and E2 is represented by E.
16 Rapid CommunicationNaCl, 20% sucrose [wt/vol], 1 mM PMSF and 1 mM DTT)
overnight at 4 °C. Human topo I was purified from extracts of
baculovirus infected SF9 cells as described (Stewart et al.,
1996).
ELISA protein–protein interaction assay
Enzyme linked immunosorbent assays (ELISA) were
performed in 96-well polyvinyl plates essentially as described.
Briefly, wells were coated for 60 min at room temperature
(RT) with purified topo I or GST-E2 in 50 μl of TBS (25 mM
Tris–HCl [pH 7.4], 150 mM NaCl) as the immobilized
protein. The wells were washed, blocked for 60 min at RT
(with 2% calf serum [vol/vol] and 5% dry milk [wt/vol] in
TBS), and washed again. Increasing concentrations of the
second protein were added to the wells and incubated for
60 min at RT in the presence of 20 U/ml of micrococcalFig. 4. Topo I does not stimulate PV origin binding by E2. (a) A fixed amount of
incubated with radiolabeled BPV-1 origin DNA for 30 min at 37 °C followed b
topo I-DNA complex and the free probe are indicated by arrows. (b) Results fr
Quantity One software. The radioactive intensity of the E2-DNA complex from e
(which was assigned a value of 1, lane 7). All results represent three separatenuclease, 1 mM MgCl2, and 1 mM CaCl2. The wells were
washed, and a polyclonal anti-GST antibody or a monoclonal
anti-topo I antibody was added for 60 min at RT. An anti-goat
or anti-mouse secondary Hrp antibody was then applied to the
wells for 45 min at RT. The wells were washed and incubated
with 50 μl of visualization solution (110 mM sodium acetate
[pH 5.5]), containing the chromogenic substrate, 3,3′,5,5′-
tetramethylbenzidine (0.02 mg/ml), and hydrogen peroxide
(0.0075% [vol/vol]). After 5 min, the reaction was stopped
with the addition of 50 μl of 2 M sulfuric acid. The assays
were quantified spectrophotometrically by absorbance at
450 nm. Each assay was performed at least three times.
Topo I plasmid relaxation assay
Plasmid template pUC119 or p7974-99 was incubated with
5 pg/μl of topo I for 30 min at 37 °C in relaxation buffer (50 mMBPV-1 E2 (2 pmol) and increasing amounts of topo I (0 to 200 fmol) were
y cross-linking with glutaraldehyde. Migration of the E2-DNA complex, the
om panel a were subjected to phosphorimager analysis and quantified using
ach lane was quantified and compared to E2 alone in the absence of topo I
experiments; the range is depicted by error bars.
17Rapid CommunicationTris [pH 7.4], 125 mM KCl, 10 mM MgCl2, 0.5 mM DTT,
0.5 mM Na2EDTA, and 0.1 mg/ml BSA) with or without GST-
E2, GST or additional BSA (see figure legends). The reactions
were stopped with EDTA, SDS, and proteinase K for 30 min at
37 °C. After extraction and precipitation, the DNA products
were applied to a 1% agarose gel (wt/vol), run at 75 V for 2 h,
and stained with ethidium bromide. Following staining, the
DNA products were visualized and quantified. Assays includ-
ing ATP, addressing order of addition, or testing various plasmid
templates were all performed in a similar manner.
Topo I plasmid relaxation assays were performed in the
presence of increasing levels of GST-E2. Topo I stimulation (of
DNA relaxation) produced by E2 (or other proteins) was
calculated by comparison with a topo I standard curve. Standard
curves were created by adding increasing amounts of topo I to a
relaxation assay. Fold stimulation was evaluated by comparing
the degree of relaxation (of form I DNA) upon stimulation to the
standard curve and calculating the fold increase in topo I
required to obtain the same degree of relaxation.
GST co-precipitations
Glutathione Sepharose beads were pre-washed in TBS and
incubated for 3 h at 4 °C while rotating either GST or GST-E2
with S100 extract from 293 cells (or purified topo I). The beads
were washed in TBS with 750 mM NaCl three times and
subjected to 12.5% SDS-PAGE and immunoblot analysis. For
immunoblotting, an anti-topo I monoclonal antibody (1:1000 in
TBS-T with 1% dry milk [wt/vol] and 4% calf serum [vol/vol])
followed by an anti-mouse Hrp antibody (1:5000 in TBS-Twith
0.5% dry milk [wt/vol] and 2% calf serum [vol/vol]) were used
to detect topo I.
Probes and nonspecific competitor DNA
BPV-1 origin DNAwas isolated from the plasmid p7914/27-
BS9 (which contains a unique high affinity E2 binding site from
the BPV-1 E2-dependent enhancer in place of E2 BS12,
Sedman and Stenlund, 1995), using restriction enzymes XbaI
and HindIII. The digested products were separated using 2%
agarose gel electrophoresis. The origin-containing fragment
was excised, gel purified, dephosphorylated using calf intestine
alkaline phosphatase (CIAP), and 32P end labeled with T4
polynucleotide kinase. The radiolabeled origin fragment was
further purified using Sephadex G-50 (Amersham Pharmacia).
Nonspecific competitor DNAwas obtained by digesting pUC19
with DdeI.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were performed by incubating 5000 cpm of
radiolabeled PVorigin DNA (∼2 fmol) with indicated proteins
in buffer containing: 20 mM HEPES-K+, pH 7.5, 100 mM
NaCl, 10% glycerol (v/v), 4 mM ATP, 7 mM Mg2+, 0.1 mg/ml
BSA, 1 mM DTT, and 1 mM EDTA in the presence of 20 ng
of nonspecific competitor DNA for 30 min at 37 °C.
Glutaraldehyde was added to a final concentration of 0.02%(vol/vol) and incubated for an additional 20 min at 25 °C.
Products were resolved using electrophoresis on a 5% native
polyacrylamide gel (79:1 acrylamide/bis-acrylamide) in
0.5× Tris–borate–EDTA (TBE) buffer (45 mM Tris–borate,
1 mM EDTA) at 4 °C. The gels were dried, and products were
analyzed using Bio-Rad FX Molecular Imager system, with
Quantity One software.
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